Loading...
•
Sep 30, 2024
Enliven Therapeutics Q3 2024 Earnings Report
Reported third quarter financial results and provided a business update, highlighting pipeline progress.
Key Takeaways
Enliven Therapeutics reported its third quarter financial results, highlighting positive data from the Phase 1 clinical trial of ELVN-001 and continued progress with ELVN-002. The company's cash position remains strong with $291.8 million, expected to provide runway into late 2026.
Announced positive data from the Phase 1 clinical trial of ELVN-001 in CML, reporting a cumulative MMR rate of 44% (8/18) by 24 weeks.
ELVN-001 remains well-tolerated with no dose reductions.
Continued to progress ELVN-002 with a focus on recently initiated combination clinical trials evaluating patients with HER2+ MBC and CRC.
Strong balance sheet with $292 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into late 2026.
Forward Guidance
Enliven plans to report additional Phase 1 data in 2025 for ELVN-001 and ELVN-002.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...